Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Retained Earnings (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Retained Earnings readings, the most recent being -$37000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 54.32% year-over-year to -$37000.0, compared with a TTM value of -$37000.0 through Dec 2025, up 54.32%, and an annual FY2025 reading of -$37000.0, up 54.32% over the prior year.
  • Retained Earnings hit -$37000.0 in Q4 2025 for Lisata Therapeutics, up from -$42000.0 in the prior quarter.
  • The five-year high for Retained Earnings was -$32000.0 in Q3 2024, with the low at -$552.8 million in Q1 2025.
  • Median Retained Earnings over the past 3 years was -$90500.0 (2023), compared with a mean of -$221.3 million.
  • The sharpest move saw Retained Earnings plummeted 92.86% in 2024, then skyrocketed 99.99% in 2025.
  • Year by year, Retained Earnings stood at -$42000.0 in 2023, then crashed by 92.86% to -$81000.0 in 2024, then soared by 54.32% to -$37000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$37000.0, -$42000.0, and -$50000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.